Drug Trial Radar · NCT00048152
A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients
Last checked: Nov 20, 2026Latest source record: Nov 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
539
Actual
Start
Dec 2000
Primary completion
Mar 2006
Study completion Mar 2006
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 25, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare kidney function in kidney transplant patients following treatment with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine). The anticipated time on study treatment is 6-12 months, and the target sample size is 500+ individuals.
Conditions
- Kidney Transplantation
Interventions
CorticosteroidsDrug
As prescribed
NeoralDrug
Low dose (target trough level 50-100ng/mL)
NeoralDrug
Standard dose (target trough level 150-300ng/mL)
ZenapaxDrug
2mg/kg iv first dose, then 1mg/kg every 2 weeks
mycophenolate mofetil [CellCept]Drug
1g po bid
Primary outcomes
What the sponsor says the trial is designed to measure.
- Renal function (as measured by GFR)Time frame: 12 months post-transplant
Locations
36 sites in 12 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
San Francisco, California
Site not named
Gainesville, Florida
Site not named
Atlanta, Georgia
Site not named
Livingston, New Jersey
Site not named
Philadelphia, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Falls Church, Virginia
Site not named
Adelaide, Australia
Site not named
Sydney, Australia
Site not named
Brussels, Belgium
Site not named
Leuven, Belgium
Site not named
Calgary, Alberta, Canada
Site not named
Edmonton, Alberta, Canada
Site not named
Vancouver, British Columbia, Canada
Site not named
Saskatoon, Saskatchewan, Canada
Site not named
Vandœuvre-lès-Nancy, France
Site not named
Berlin, Germany
Site not named
Hanover, Germany
Site not named
Münster, Germany
Site not named
Mexico City, Mexico
Site not named
Monterrey, Mexico
Site not named
Oslo, Norway
Site not named
Warsaw, Poland
Site not named
Wroclaw, Poland
Site not named
Barcelona, Spain
Site not named
Barcelona, Spain
Site not named
Córdoba, Spain
Site not named
Málaga, Spain
Site not named
Santander, Spain
Site not named
Valencia, Spain
Site not named
Gothenburg, Sweden
Site not named
Malmö, Sweden
Site not named
Birmingham, United Kingdom
Site not named
Glasgow, United Kingdom
Site not named
Leicester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.